{"pmid":32320211,"title":"Neurological Insights of COVID-19 Pandemic.","text":["Neurological Insights of COVID-19 Pandemic.","The novel coronavirus SARS-CoV-2, which was identified after a recent outbreak in Wuhan, China, in December 2019, has kept the whole world in tenterhooks due to its severe life-threatening nature of the infection. The virus is unlike its previous counterparts, SARS-CoV and MERS-CoV, or anything the world has encountered before both in terms of virulence and severity of the infection. If scientific reports relevant to the SARS-CoV-2 virus are noted, it can be seen that the virus owes much of its killer properties to its unique structure that has a stronger binding affinity with the human angiotensin-converting enzyme 2 (hACE2) protein, which the viruses utilize as an entry point to gain accesses to its hosts. Recent reports suggest that it is not just the lung that the virus may be targeting; the human brain may soon emerge as the new abode of the virus. Already instances of patients with COVID-19 have been reported with mild (anosmia and ageusia) to severe (encephalopathy) neurological manifestations, and if that is so, then it gives us more reasons to be frightened of this killer virus. Keeping in mind that the situation does not worsen from here, immediate awareness and more thorough research regarding the neuroinvasive nature of the virus is the immediate need of the hour. Scientists globally also need to up their game to design more specific therapeutic strategies with the available information to counteract the pandemic. In this Viewpoint, we provide a brief outline of the currently known neurological manifestations of COVID-19 and discuss some probable ways to design therapeutic strategies to overcome the present global crisis.","ACS Chem Neurosci","Das, Gaurav","Mukherjee, Nabanita","Ghosh, Surajit","32320211"],"abstract":["The novel coronavirus SARS-CoV-2, which was identified after a recent outbreak in Wuhan, China, in December 2019, has kept the whole world in tenterhooks due to its severe life-threatening nature of the infection. The virus is unlike its previous counterparts, SARS-CoV and MERS-CoV, or anything the world has encountered before both in terms of virulence and severity of the infection. If scientific reports relevant to the SARS-CoV-2 virus are noted, it can be seen that the virus owes much of its killer properties to its unique structure that has a stronger binding affinity with the human angiotensin-converting enzyme 2 (hACE2) protein, which the viruses utilize as an entry point to gain accesses to its hosts. Recent reports suggest that it is not just the lung that the virus may be targeting; the human brain may soon emerge as the new abode of the virus. Already instances of patients with COVID-19 have been reported with mild (anosmia and ageusia) to severe (encephalopathy) neurological manifestations, and if that is so, then it gives us more reasons to be frightened of this killer virus. Keeping in mind that the situation does not worsen from here, immediate awareness and more thorough research regarding the neuroinvasive nature of the virus is the immediate need of the hour. Scientists globally also need to up their game to design more specific therapeutic strategies with the available information to counteract the pandemic. In this Viewpoint, we provide a brief outline of the currently known neurological manifestations of COVID-19 and discuss some probable ways to design therapeutic strategies to overcome the present global crisis."],"journal":"ACS Chem Neurosci","authors":["Das, Gaurav","Mukherjee, Nabanita","Ghosh, Surajit"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32320211","week":"202017|Apr 20 - Apr 26","doi":"10.1021/acschemneuro.0c00201","keywords":["covid-19","sars-cov-2","encephalopathy","hace2","neuroinvasive property","therapeutic intervention"],"source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664815087667380225,"score":8.518259,"similar":[{"pmid":32333487,"title":"Does SARS-Cov-2 invade the brain? Translational lessons from animal models.","text":["Does SARS-Cov-2 invade the brain? Translational lessons from animal models.","The current coronavirus disease (COVID-19) outbreak, caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has raised the possibility of potential neurotropic properties of this virus. Indeed, neurological sequelae of SARS-CoV-2 infection have already been reported and highlight the relevance of considering the neurological impact of coronavirus from a translational perspective. Animal models of SARS and Middle East respiratory syndrome (MERS), caused by structurally similar coronaviruses during the 2002 and 2012 epidemics, have provided valuable data on nervous system involvement by coronaviruses and the potential for CNS spread of SARS-CoV-2. One key finding that may unify these pathogens is that all require angiotensin-converting enzyme 2 (ACE2) as a cell entry receptor. The CoV spike glycoprotein, by which SARS_CoV-2 binds to cell membranes, binds ACE2 with a higher affinity compared to SARS-CoV. The expression of this receptor in neurons and endothelial cells hints that SARS-CoV-2 may have higher neuroinvasive potential compared to previous coronaviruses. Yet, how such invasiveness might contribute to respiratory failure or cause direct neurological damage remains to be determined. Both direct and indirect mechanisms may be of relevance. Clinical heterogeneity potentially driven by differential host immune-mediated responses will require extensive investigation. Development of disease models to anticipate emerging neurological complications and to explore mechanisms of direct or immune-mediated pathogenicity in the short- and medium- term is therefore of great importance. In this brief review, we describe the current knowledge from models of previous coronavirus infections and discuss their potential relevance to COVID-19.","Eur J Neurol","Natoli, Silvia","Oliveira, Vanessa","Calabresi, Paolo","Maia, Luis F","Pisani, Antonio","32333487"],"abstract":["The current coronavirus disease (COVID-19) outbreak, caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has raised the possibility of potential neurotropic properties of this virus. Indeed, neurological sequelae of SARS-CoV-2 infection have already been reported and highlight the relevance of considering the neurological impact of coronavirus from a translational perspective. Animal models of SARS and Middle East respiratory syndrome (MERS), caused by structurally similar coronaviruses during the 2002 and 2012 epidemics, have provided valuable data on nervous system involvement by coronaviruses and the potential for CNS spread of SARS-CoV-2. One key finding that may unify these pathogens is that all require angiotensin-converting enzyme 2 (ACE2) as a cell entry receptor. The CoV spike glycoprotein, by which SARS_CoV-2 binds to cell membranes, binds ACE2 with a higher affinity compared to SARS-CoV. The expression of this receptor in neurons and endothelial cells hints that SARS-CoV-2 may have higher neuroinvasive potential compared to previous coronaviruses. Yet, how such invasiveness might contribute to respiratory failure or cause direct neurological damage remains to be determined. Both direct and indirect mechanisms may be of relevance. Clinical heterogeneity potentially driven by differential host immune-mediated responses will require extensive investigation. Development of disease models to anticipate emerging neurological complications and to explore mechanisms of direct or immune-mediated pathogenicity in the short- and medium- term is therefore of great importance. In this brief review, we describe the current knowledge from models of previous coronavirus infections and discuss their potential relevance to COVID-19."],"journal":"Eur J Neurol","authors":["Natoli, Silvia","Oliveira, Vanessa","Calabresi, Paolo","Maia, Luis F","Pisani, Antonio"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32333487","week":"202017|Apr 20 - Apr 26","doi":"10.1111/ene.14277","keywords":["covid-19","sars-cov-2","animal models","coronavirus","neurotropism","systematic review","viral infections"],"source":"PubMed","topics":["Mechanism"],"weight":1,"_version_":1665071049676423168,"score":325.29706},{"pmid":32167747,"pmcid":"PMC7094171","title":"Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms.","text":["Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms.","The recent outbreak of coronavirus infectious disease 2019 (COVID-19) has gripped the world with apprehension and has evoked a scare of epic proportion regarding its potential to spread and infect humans worldwide. As we are in the midst of an ongoing pandemic of COVID-19, scientists are struggling to understand how it resembles and differs from the severe acute respiratory syndrome coronavirus (SARS-CoV) at the genomic and transcriptomic level. In a short time following the outbreak, it has been shown that, similar to SARS-CoV, COVID-19 virus exploits the angiotensin-converting enzyme 2 (ACE2) receptor to gain entry inside the cells. This finding raises the curiosity of investigating the expression of ACE2 in neurological tissue and determining the possible contribution of neurological tissue damage to the morbidity and mortality caused by COIVD-19. Here, we investigate the density of the expression levels of ACE2 in the CNS, the host-virus interaction and relate it to the pathogenesis and complications seen in the recent cases resulting from the COVID-19 outbreak. Also, we debate the need for a model for staging COVID-19 based on neurological tissue involvement.","ACS Chem Neurosci","Baig, Abdul Mannan","Khaleeq, Areeba","Ali, Usman","Syeda, Hira","32167747"],"abstract":["The recent outbreak of coronavirus infectious disease 2019 (COVID-19) has gripped the world with apprehension and has evoked a scare of epic proportion regarding its potential to spread and infect humans worldwide. As we are in the midst of an ongoing pandemic of COVID-19, scientists are struggling to understand how it resembles and differs from the severe acute respiratory syndrome coronavirus (SARS-CoV) at the genomic and transcriptomic level. In a short time following the outbreak, it has been shown that, similar to SARS-CoV, COVID-19 virus exploits the angiotensin-converting enzyme 2 (ACE2) receptor to gain entry inside the cells. This finding raises the curiosity of investigating the expression of ACE2 in neurological tissue and determining the possible contribution of neurological tissue damage to the morbidity and mortality caused by COIVD-19. Here, we investigate the density of the expression levels of ACE2 in the CNS, the host-virus interaction and relate it to the pathogenesis and complications seen in the recent cases resulting from the COVID-19 outbreak. Also, we debate the need for a model for staging COVID-19 based on neurological tissue involvement."],"journal":"ACS Chem Neurosci","authors":["Baig, Abdul Mannan","Khaleeq, Areeba","Ali, Usman","Syeda, Hira"],"date":"2020-03-14T11:00:00Z","year":2020,"_id":"32167747","week":"202011|Mar 09 - Mar 15","doi":"10.1021/acschemneuro.0c00122","keywords":["ace2 tissue distribution","covid-19","coronavirus","sars-cov-2","host-virus interaction","spike protein"],"link_comment_in":"32233443","source":"PubMed","topics":["Mechanism"],"weight":1,"_version_":1664640874727866370,"score":287.27042},{"pmid":32275855,"pmcid":"PMC7144619","title":"Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2.","text":["Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2.","The recent emergence of a novel coronavirus (SARS-CoV-2) in China has caused significant public health concerns. Recently, ACE2 was reported as an entry receptor for SARS-CoV-2. In this study, we present the crystal structure of the C-terminal domain of SARS-CoV-2 (SARS-CoV-2-CTD) spike (S) protein in complex with human ACE2 (hACE2), which reveals a hACE2-binding mode similar overall to that observed for SARS-CoV. However, atomic details at the binding interface demonstrate that key residue substitutions in SARS-CoV-2-CTD slightly strengthen the interaction and lead to higher affinity for receptor binding than SARS-RBD. Additionally, a panel of murine monoclonal antibodies (mAbs) and polyclonal antibodies (pAbs) against SARS-CoV-S1/receptor-binding domain (RBD) were unable to interact with the SARS-CoV-2 S protein, indicating notable differences in antigenicity between SARS-CoV and SARS-CoV-2. These findings shed light on the viral pathogenesis and provide important structural information regarding development of therapeutic countermeasures against the emerging virus.","Cell","Wang, Qihui","Zhang, Yanfang","Wu, Lili","Niu, Sheng","Song, Chunli","Zhang, Zengyuan","Lu, Guangwen","Qiao, Chengpeng","Hu, Yu","Yuen, Kwok-Yung","Wang, Qisheng","Zhou, Huan","Yan, Jinghua","Qi, Jianxun","32275855"],"abstract":["The recent emergence of a novel coronavirus (SARS-CoV-2) in China has caused significant public health concerns. Recently, ACE2 was reported as an entry receptor for SARS-CoV-2. In this study, we present the crystal structure of the C-terminal domain of SARS-CoV-2 (SARS-CoV-2-CTD) spike (S) protein in complex with human ACE2 (hACE2), which reveals a hACE2-binding mode similar overall to that observed for SARS-CoV. However, atomic details at the binding interface demonstrate that key residue substitutions in SARS-CoV-2-CTD slightly strengthen the interaction and lead to higher affinity for receptor binding than SARS-RBD. Additionally, a panel of murine monoclonal antibodies (mAbs) and polyclonal antibodies (pAbs) against SARS-CoV-S1/receptor-binding domain (RBD) were unable to interact with the SARS-CoV-2 S protein, indicating notable differences in antigenicity between SARS-CoV and SARS-CoV-2. These findings shed light on the viral pathogenesis and provide important structural information regarding development of therapeutic countermeasures against the emerging virus."],"journal":"Cell","authors":["Wang, Qihui","Zhang, Yanfang","Wu, Lili","Niu, Sheng","Song, Chunli","Zhang, Zengyuan","Lu, Guangwen","Qiao, Chengpeng","Hu, Yu","Yuen, Kwok-Yung","Wang, Qisheng","Zhou, Huan","Yan, Jinghua","Qi, Jianxun"],"date":"2020-04-11T11:00:00Z","year":2020,"_id":"32275855","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.cell.2020.03.045","keywords":["ace2","ctd","sars-cov-2","crystal structure","immunogenicity","receptor","receptor binding domain"],"source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664637190193283072,"score":284.46637},{"pmid":32332765,"title":"Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig.","text":["Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig.","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, at the end of 2019, and there are currently no specific antiviral treatments or vaccines available. SARS-CoV-2 has been shown to use the same cell entry receptor as SARS-CoV, angiotensin-converting enzyme 2 (ACE2). In this report, we generate a recombinant protein by connecting the extracellular domain of human ACE2 to the Fc region of the human immunoglobulin IgG1. A fusion protein containing an ACE2 mutant with low catalytic activity is also used in this study. The fusion proteins are then characterized. Both fusion proteins have a high binding affinity for the receptor-binding domains of SARS-CoV and SARS-CoV-2 and exhibit desirable pharmacological properties in mice. Moreover, the fusion proteins neutralize virus pseudotyped with SARS-CoV or SARS-CoV-2 spike proteins in vitro. As these fusion proteins exhibit cross-reactivity against coronaviruses, they have potential applications in the diagnosis, prophylaxis, and treatment of SARS-CoV-2.","Nat Commun","Lei, Changhai","Qian, Kewen","Li, Tian","Zhang, Sheng","Fu, Wenyan","Ding, Min","Hu, Shi","32332765"],"abstract":["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, at the end of 2019, and there are currently no specific antiviral treatments or vaccines available. SARS-CoV-2 has been shown to use the same cell entry receptor as SARS-CoV, angiotensin-converting enzyme 2 (ACE2). In this report, we generate a recombinant protein by connecting the extracellular domain of human ACE2 to the Fc region of the human immunoglobulin IgG1. A fusion protein containing an ACE2 mutant with low catalytic activity is also used in this study. The fusion proteins are then characterized. Both fusion proteins have a high binding affinity for the receptor-binding domains of SARS-CoV and SARS-CoV-2 and exhibit desirable pharmacological properties in mice. Moreover, the fusion proteins neutralize virus pseudotyped with SARS-CoV or SARS-CoV-2 spike proteins in vitro. As these fusion proteins exhibit cross-reactivity against coronaviruses, they have potential applications in the diagnosis, prophylaxis, and treatment of SARS-CoV-2."],"journal":"Nat Commun","authors":["Lei, Changhai","Qian, Kewen","Li, Tian","Zhang, Sheng","Fu, Wenyan","Ding, Min","Hu, Shi"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32332765","week":"202017|Apr 20 - Apr 26","doi":"10.1038/s41467-020-16048-4","source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1665071049692151808,"score":280.96002},{"pmid":32238438,"title":"Does COVID19 Infect the Brain? If So, Smokers Might Be at a Higher Risk.","text":["Does COVID19 Infect the Brain? If So, Smokers Might Be at a Higher Risk.","COVID19 is a devastating global pandemic with epicenters in China, Italy, Spain, and now the United States. While the majority of infected cases appear mild, in some cases, individuals present serious cardiorespiratory complications with possible long-term lung damage. Infected individuals report a range of symptoms from headaches to shortness of breath to taste and smell loss. To that end, less is known about how the virus may impact different organ systems. The SARS-CoV2 virus, which is responsible for COVID19, is highly similar to SARS-CoV. Both viruses have evolved an ability to enter host cells through direct interaction with the angiotensin converting enzyme (ACE) 2 protein at the surface of many cells. Published findings indicate that SARS-CoV can enter the human nervous system with evidence from both postmortem brains and detection in cerebrospinal fluid of infected individuals. Here, we consider the ability of SARS-CoV2 to enter and infect the human nervous system based on the strong expression of the ACE2 target throughout the brain. Moreover, we predict that nicotine exposure through various kinds of smoking (cigarettes, electronic cigarettes, or vape) can increase the risk for COVID19 neuroinfection based on known functional interactions between the nicotinic receptor and ACE2. We advocate for higher surveillance and analysis of neurocomplications in infected cases. SIGNIFICANCE STATEMENT: The COVID19 epidemic has spurred a global public health crisis. While many of the cases requiring hospitalization and intensive medical care center on cardiorespiratory treatment, a growing number of cases present neurological symptoms. Viral entry into the brain now appears a strong possibility with deleterious consequences and an urgent need for addressing.","Mol Pharmacol","Kabbani, Nadine","Olds, James L","32238438"],"abstract":["COVID19 is a devastating global pandemic with epicenters in China, Italy, Spain, and now the United States. While the majority of infected cases appear mild, in some cases, individuals present serious cardiorespiratory complications with possible long-term lung damage. Infected individuals report a range of symptoms from headaches to shortness of breath to taste and smell loss. To that end, less is known about how the virus may impact different organ systems. The SARS-CoV2 virus, which is responsible for COVID19, is highly similar to SARS-CoV. Both viruses have evolved an ability to enter host cells through direct interaction with the angiotensin converting enzyme (ACE) 2 protein at the surface of many cells. Published findings indicate that SARS-CoV can enter the human nervous system with evidence from both postmortem brains and detection in cerebrospinal fluid of infected individuals. Here, we consider the ability of SARS-CoV2 to enter and infect the human nervous system based on the strong expression of the ACE2 target throughout the brain. Moreover, we predict that nicotine exposure through various kinds of smoking (cigarettes, electronic cigarettes, or vape) can increase the risk for COVID19 neuroinfection based on known functional interactions between the nicotinic receptor and ACE2. We advocate for higher surveillance and analysis of neurocomplications in infected cases. SIGNIFICANCE STATEMENT: The COVID19 epidemic has spurred a global public health crisis. While many of the cases requiring hospitalization and intensive medical care center on cardiorespiratory treatment, a growing number of cases present neurological symptoms. Viral entry into the brain now appears a strong possibility with deleterious consequences and an urgent need for addressing."],"journal":"Mol Pharmacol","authors":["Kabbani, Nadine","Olds, James L"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32238438","week":"202014|Mar 30 - Apr 05","doi":"10.1124/molpharm.120.000014","source":"PubMed","topics":["Mechanism"],"weight":1,"locations":["China","Italy","Spain","United States"],"countries":["Spain","United States","China","Italy"],"countries_codes":["ESP|Spain","USA|United States","CHN|China","ITA|Italy"],"e_drugs":["Nicotine"],"_version_":1664638354320261121,"score":267.9912}]}